Lilly’s latest China drug deal; Immunovant’s setback in lupus
Published . Updated .
Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.
Directly affected
Indirectly affected
- CPHI CHINA PHARMA HLDGS INC
GA selected CPHI as a RELATED security because its canonical security name directly matches this event's themes: pharma, china. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.
Source: BioPharma Dive
Immunovant (IMVT) since this story, compared with the market
Since the first closing price after “Lilly’s latest China drug deal; Immunovant’s setback in lupus,” Immunovant (IMVT) is -17.18%. The S&P 500 fund (SPY) is -0.62% over the same days, a -16.56% difference versus the market.
Who reported a Immunovant (IMVT) trade near this story
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Immunovant (IMVT)
Companies carried with this story
- IMVT Immunovant
In “Lilly’s latest China drug deal; Immunovant’s setback in lupus,” Immunovant (IMVT) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names IMMUNOVANT INC in the headline; GA resolved that company to IMVT
- CPHI China Pharma Holdings
In “Lilly’s latest China drug deal; Immunovant’s setback in lupus,” China Pharma Holdings (CPHI) is linked, with no stored direction, medium confidence. Reason on file: GA selected CPHI as a RELATED security because its canonical security name directly matches this event's themes: pharma, china. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ACHC Acadia Healthcare
Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence in the 24 Sep 2026 story “Lilly’s latest China drug deal; Immunovant’s setback in lupus.” Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence in the 24 Sep 2026 story “Lilly’s latest China drug deal; Immunovant’s setback in lupus.” Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
In “Lilly’s latest China drug deal; Immunovant’s setback in lupus,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
In “Lilly’s latest China drug deal; Immunovant’s setback in lupus,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
For “Lilly’s latest China drug deal; Immunovant’s setback in lupus,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Immunovant (IMVT)
On 24 Sep 2026, “Lilly’s latest China drug deal; Immunovant’s setback in lupus” is the story that connects Immunovant (IMVT) to this story.
For Immunovant (IMVT), the reason on file says The reported development directly names IMMUNOVANT INC in the headline; GA resolved that company to IMVT
A second company, China Pharma Holdings (CPHI), is listed for a different reason: GA selected CPHI as a RELATED security because its canonical security name directly matches this event's themes: pharma, china. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the Immunovant (IMVT) price range
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. CPHI traded between 0.64 and 1.28 across 20 sessions. The latest close on file is 0.67. IMVT traded between 26.26 and 37.68 across 20 sessions. The latest close on file is 27.58.
How strong the case is around Immunovant (IMVT)
46 out of 100
“Lilly’s latest China drug deal; Immunovant’s setback in lupus” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.